Newsroom
Follow Our Journey On Social Media
Latest News
BrYet Files IND Application for ML-016, Lead Oncology Therapeutic for Advanced Solid Tumors with Lung and/or Liver Metastases
HOUSTON (March 4, 2026) — BrYet US, Inc. (“BrYet”) — a biotechnology innovator focused on developing curative therapies for advanced cancers — announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead drug, ML-016. Upon approval, the IND will support the expansion of...
BrYet US, Inc. Expands Patent Portfolio with New U.S. Patent for Targeted Drug Delivery
Near-term applications include combinations with kinase inhibitors (KIs) that achieve enhanced concentration at target sites and synergistic delivery of multiple KIs to the same location HOUSTON (November 13, 2025) — BrYet US, Inc. — a biotechnology innovator focused on developing curative therapies for advanced cancers — announced today that it has...
BrYet US, Inc. Receives Approval to Initiate in Australia a First-in-Human Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement
HOUSTON and SUNSHINE COAST, Queensland (October 6, 2025) — BrYet US, Inc. (“BrYet”), a biotechnology innovator developing a drug with the potential to be a first-in-class medicine for metastatic disease, today announced that it has received an Australian Human Research Ethics Committee (HREC) approval for its first-in-human clinical study of ML-016....
Results Published In Leading Scientific Journals
Nature Biotechnology
An injectible nanoparticle generator enhances delivery of cancer therapeutics
Science Advances
Sequential deconstruction of composite drug transport in metastatic breast cancer
Nature Reviews Cancer
Approaches from the physical sciences can contribute to the rate at which powerful new diagnostic tools and therapies can be discovered.